As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

Leading data and analytics company GlobalData’s report, Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast, ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker programs to pay kickbacks to doctors to induce them to prescribe Gilead’s ...

Pharmaceutical firm Gilead has admitted paying hundreds of thousands of dollars in illegal kickbacks to US doctors between ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening, offset lower cancer drug sales.

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...

Metformin use in patients with HIV and type 2 diabetes who had at least 2 years of exposure to effective ART showed no significant effect on immune reconstitution.

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...